Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Launched by THE SECOND HOSPITAL OF SHANDONG UNIVERSITY · Dec 25, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of immunotherapy combined with chemotherapy in patients who have had surgery for esophageal cancer or cancer at the esophageal-gastric junction. The goal is to see if this combination can help patients live longer without their cancer coming back, especially for those who may not have responded well to earlier treatments. The trial is open to adults aged 18 and older who have a specific type of esophageal cancer that can be removed with surgery and are generally healthy enough to undergo the procedure.

If you participate in this trial, you will receive either the standard chemotherapy treatment or the new combination of chemotherapy and immunotherapy after your surgery. The study will monitor how well the treatment works, any side effects you may experience, and how it affects your quality of life. It's important to note that this trial is currently recruiting participants, so if you think you might be eligible, you could have the chance to explore this new treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and lung function can tolerate surgery. The cancer is resectable and incurable therapy will be perfomed.
• Exclusion Criteria:
• • EG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection Status.